Supported projects

Ongoing projects

AXIS 1: CLINICAL AND TREATMENT RESEARCH

Healthy Brains, Healthy Lives: The McGill Brain Health Outcomes Platform (BHOP) - Mayo, BSc PT. PhD – McGill University

Real-time Auditory Feedback for Improving Gait and Walking in People with Parkinson’s Disease – Mayo, BSc PT. PhD – McGill University

Contribution of kinematic theory to early differential diagnosis of Parkinson’s disease – Blanchet, MD, PhD – Université de Montréal

Pre-clinical and clinical assessment of neurofibrillary tangles using novel tau ligand [18F]PI-2620 and assessment of synaptic density using another novel ligand [18F]SDM-8 : a pilot study – Rosa-Neto, MD PhD – McGill University

A Phase 1 Single- and Multiple-Ascending-Dose study to assess the safety, tolerability, and pharmacokinetics of BIIB094 administered intrathecally to adults with Parkinson’s disease – Postuma, MD – McGill University

Development of a novel, inexpensive and accessible battery of eye-tracking tests for diagnostic, disease progression, and response-to-treatment assessments of neurological disorders – Ducharme, MD – McGill University

Novel tools for the delivery and assessment of exercise programs adapted to individuals with Parkinson’s disease – Duval, PhD – Université du Québec à Montréal

The genetics of REM sleep behavior disorder, Parkinson’s disease and other synucleinopathies - Gan-Or, PhD – McGill University

Study of Electroretinogram (ERG) and Oral Bacteria in Parkinson’s disease: A Study of Markers in Parkinson’s disease – Lévesque, PhD – Université Laval

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson’s Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation – Sanofi / Genzyme

Assessment of Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy - Postuma, MD, PhD – McGill University – Corporation abbVie

Behavioral and neuroimaging biomarkers of Parkinson’s Disease: Neuroimaging stream - Doyon, PhD – Université de Montréal and McGill University

Validation of a mobile app for the detection of tremors and bradykinesia – Duval, PhD – Université du Québec à Montréal

Exploratory study for the validation of magnetic resonance imaging biomarkers for Parkinson’s disease – Soucy, MD, PhD – Concordia University, Université de Montréal and CHUS

Effect of long-acting levodopa on obstructive sleep apnea in Parkinson’s disease – Kaminska, MD, MSc – McGill University

National Parkinson Foundation Patient Registry – Lafontaine, MD, MSC – McGill University / National Parkinson Foundation

Imaging brain structures involved in human walking with Parkinson’s disease (PD) – Paquette, PhD, Dr Soucy, MD – McGill University

A novel exercise modality to improve motor learning in PD - Roig, PhD – McGill University

AXIS 2: NON-MOTOR SYMPTOMS

Study of activity and functional connectivity in response to trigeminal odor in Parkinson’s disease - Frasnelli, PhD – Université du Québec à Trois-Rivières

Lighting-up the brain of patients with Parkinson’s disease – Carrier, PhD – Université de Montréal

Effects of Parkinson’s disease on social cognition and communication – Pell, PhD – McGill University

Longitudinal behavioral and neuroimaging study for the identification of language markers aimed at the earlier and more accurate prediction, detection, and tracking of cognitive decline over time in Parkinson’s disease – Auclair-Ouellet, PhD – McGill University

Understanding resilience and disease by using language and the brain to predict individual outcomes – Klein, PhD – McGill University

Identification of a specific olfactory disease profile in Parkinson’s disease – Frasnelli, PhD – Université du Québec à Trois-Rivières

Auditory  dysfunction  associated  with Parkinson’s  disease: a pilot study characterizing  the peripheral and central auditory signs in Parkinson’s  disease - Fuente, PhD – Uniersité de Montréal

Role of dopamine in prioritizing memory content: Implications for Parkinson’s disease – Sharp, MD, MSc – McGill University

Quantitative Motor Control for Decision-Making (QTMODEM) – Messier, PhD – Université de Montréal

MRI and Virtual Navigational Strategies in Parkinson’s Disease – Bohbot, PhD – McGill University and Université de Montréal

Role of brain cholinergic degenerations in the Mild Cognitive Impairment of Parkinson’s disease: A PET study with the 18F-Fluoroethoxybenzovesamicol (FEOBV) – Bédard, PhD, Soucy, MD, Dagher, MD – Université du Québec à Montréal, Université de Montréal and McGill University

AXIS 3: MOLECULAR AND CELLULAR BIOLOGY

Validation of salivary heme oxygenase-1 as a biomarker of idiopathic Parkinson’s disease – Schipper, MD, Ph. D – McGill University

Open Science Clinical Biological Imaging and Genetic Repository – C-BIG Repository

Targeted Next-Generation Sequencing and Genome-Wide Association Study of Parkinson’s disease patients in Quebec - Rouleau MD – McGill University

Epidemiological and genetic study of Parkinson’s disease in Quebec - Dupré, MD – CHU de Québec

Clinical – Genetic study of GBA mutations in Parkinson’s disease and REM sleep Behavior Disorder

———————————————————————————————–

Completed Project

AXIS 1: CLINICAL AND TREATMENT RESEARCH

Study on the effect of Mirtazapine on depression in patients diagnosed with Parkinson’s disease

Home and community mobility in elderly healthy individuals ans patients with Parkinson’s disease

The impact of drug-induced dyskinesia and its management on daily-life activities

Assessment of gait sensors for Parkinson’s disease

Comparison of the efficiency of levodopa and dopamine agonists on the mobility in the community and the physical activity level of people with Parkinson’s disease

Behavioral and neuroimaging biomarkers of Parkinson’s Disease: Behavioral stream – Doyon, PhD – UdeM and McGill

Impact of an exercise program on proprioceptive performance in Parkinson’s disease

Treatment of sleep apnea in Parkinson’s disease

Detection and automatic follow-up of the motor symptoms in patients with Parkinson’s disease

Caffeine as a Therapeutic Agent in Parkinson’s disease

Association of Cognitive dysfunction with Orthostatic Hypotension in patients with Parkinson’s disease

Validation of the Movement Disorders Society PD diagnostic criteria

The effect of cardiorespiratory exercice on motor skill learning in Parkinson’s disease

Freezing mechanisms in Parkinson’s disease

AXIS 2: NON-MOTOR SYMPTOMS

Smoking and Cognition in Parkinson’s disease

Cognitive effect of transcranial magnetic stimulation on patients with Parkinson’s disease and mild cognitive impairment

The Physical and Cognitive Benefits of Dance Movement Therapy for People with Parkinson’s Disease

Cognitive Reserve and Parkinson Disease : Can an extra Language help in more ways than one ?

Studying the resting-state networks associated with cognitive deficits in Parkinson’s disease

The effects of eye-movement training on cognitive performance

Perceptual-Cognitive Training in Parkinon’s disease

Electrical Brain Stitmulation and Impulsive Control Disorders

AXIS 3: MOLECULAR AND CELLULAR BIOLOGY

Genome wide association study of Parkinson’s disease and REM sleep Behavior Disorder

Targeted next generation sequencing of 58 Parkinson’s disease- related genes

The role of SMPD1 in Parkinson’s disease

Association study of the melanoma gene MC1R and Parkinson’s disease

The interplay between nicotinic receptor and nicotine metabolism genes, smoking and Parkinson’s disease

DNAJC13 in Parkinson’s disease

Study of novel familial genes in Parkinson’s disease

Replication study of essential tremor genetic loci in Parkinson’s disease

Study of HIP1R, LRRK2 and SNCA in Parkinson’s disease